Skip to main content
OpenTrials
Completed

NCT Number: NCT05452616

Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis

SaDAPT is a pragmatic, randomized, therapeutic-use trial comparing two approaches ("ART first" versus "TB results first") for the timing of ART initiation in PLHIV with presumptive TB, but no signs of central nervous system (CNS) disease, in a routine primary and secondary care setting in southern Africa with regard to HIV viral suppression (VL <400 copies/mL) 26 weeks after enrolment.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In this randomized controlled trial (RCT) two different, guideline-approved algorithms for antiretroviral therapy (ART) initiation in people living with HIV (PLHIV) with presumptive Tuberculosis (TB), but no signs of central nervous system (CNS) disease will be compared. In one arm, same-day initiation (SDI) of ART will be applied ("ART first") for all participants independent of the status or results of initial TB investigations. In the other arm, an approach with deferral of ART initiation until TB is excluded or confirmed and TB treatment initiated will be applied ("TB results first"). The direct comparison of the two approaches in a pragmatic, two-country RCT conducted in a representative high-prevalence setting will provide evidence on the open question of optimal timing of ART initiation in the large subgroup of PLHIV with presumptive TB outside the CNS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 12 years or older
  • HIV-positive
  • Not taking ART (naïve or reported no ART intake since 90 days or more)
  • Presenting with one or more TB symptoms according to W4SS
  • Unknown TB status
  • Planning to continue care at the study facility for at least 30 weeks
  • Willing and able to consent (age 18 years or older) or assent with guardian consent (age 12 to 17 years)

Exclusion criteria

  • Medical condition requiring admission or referral to a higher level health facility at enrolment
  • Symptoms or clinical signs suggestive for diseases of the CNS
  • Positive cryptococcal antigen test (CrAg)
  • Reporting to be pregnant
  • Taking TB treatment, TB preventive therapy (TPT) or treatment against cryptococcal meningitis

Treatment and study plan

ART first- Therapeutic use trial

Other

ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.

TB results first- Therapeutic use trial

Other

Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.

Primary outcomes

  1. HIV viral suppression <400 copies/mL

    Time frame: 26 (22 - 40) weeks after enrolment

    HIV viral suppression <400 copies/mL (obtained from routine laboratory reports at study facility, from laboratory reports of referral facility in case of transfer out, or from dried blood spot (DBS) sample for participants without documented clinic visit but found during home visit tracing)

Secondary outcomes

  1. Retention in care

    Time frame: 26 (22 - 30) weeks after enrolment

    Retention in care, defined as a documented ART clinic visit between 22 and 30 weeks after enrolment

  2. Engagement in care

    Time frame: 26 (22 - 30) weeks after enrolment

    Engagement in care, defined as reporting regular ART intake, irrespective if a documented visit took place between 22 and 30 weeks after enrolment

  3. Disengagement from care

    Time frame: 26 (22 - 30) weeks after enrolment

    Disengagement from care, defined as non-engaged in care but reached through patient tracing

  4. Lost to follow-up

    Time frame: 26 (22 - 30) weeks after enrolment

    Lost to follow-up, defined as non-retained in care and not reached through tracing

  5. Non-traumatic mortality

    Time frame: during the first 30 weeks after enrolment

    Non-traumatic mortality

  6. Serious adverse events (SAEs)

    Time frame: during the first 30 weeks after enrolment

    SAEs

  7. TB-Immune reconstitution inflammatory syndrome (IRIS)

    Time frame: during the first 30 weeks after enrolment

    TB-Immune reconstitution inflammatory syndrome (IRIS) is defined as Adverse event of special interest (AESIs): AESIs

  8. Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis)

    Time frame: during the first 30 weeks after enrolment

    Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis), defined as any TB diagnosis after enrolment not classified as prevalent TB at enrolment

  9. HIV viral suppression

    Time frame: at 26 (22 - 40) weeks

    HIV viral suppression using different thresholds (<20 copies/mL; <100 copies/mL; <1000 copies/mL)

Other outcomes

  1. Prevalence of active TB diagnosed at enrolment (exploratory endpoint)

    Time frame: up to a maximum of 28 days after enrolment

    Prevalence of active TB, defined as TB diagnosed clinically or microbiologically through the TB investigations at enrolment

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Collaborators

  • Kamuzu University of Health Sciences
  • London School of Hygiene and Tropical Medicine
  • Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • SolidarMed
  • Swiss National Science Foundation
  • Swiss Tropical & Public Health Institute

Registry information

Official study title

Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis: an Open-label Randomized Non-inferiority Trial in Lesotho and Blantyre District, Malawi

Acronym: SaDAPT

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
Jul 11, 2022
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.